Search

Displaying results 9731 - 9740 of 9860 in total
  1. Drug

    SLN500

    go.drugbank.com/drugs/DB18636
    Experimental

    SLN500 is a synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA

  2. Drug

    AVR-RD-04

    go.drugbank.com/drugs/DB18644
    Experimental

    It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.

    Synonyms: autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin
  3. Drug

    Divesiran

    go.drugbank.com/drugs/DB18646
    Investigational

    Divesiran is a synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing 3 N-acetylgalactosamine residues.

  4. Drug

    PARPI F-18

    go.drugbank.com/drugs/DB18657
    Experimental

    PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.

  5. Drug

    Canvuparatide

    go.drugbank.com/drugs/DB18658
    Investigational

    Canvuparatide is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.[L48365]

  6. Drug

    RGG0853

    go.drugbank.com/drugs/DB18669
    Experimental

    RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.

  7. Drug

    SM-1997

    go.drugbank.com/drugs/DB18670
    Experimental

    SM-1997 is a protein-free solution derived from calf's blood comprising electrolytes, trace minerals, amino acids, peptides, nucleosides, and nucleotides.

  8. Drug

    NDX-3315

    go.drugbank.com/drugs/DB18671
    Investigational

    It is a technetium-99m radiolabeled [heparin].

  9. Drug

    Ozekibart

    go.drugbank.com/drugs/DB18675
    Investigational

    Ozekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.

  10. Drug

    MBP134

    go.drugbank.com/drugs/DB18686
    Experimental

    MBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).